Our experience with the treatment of primary lymphomas of the central nervous system

Česká verzia

Authors: M. Motyčková; L. Smolej; D. Belada; J. Malý; P. Žák
Authors place of work: IV. interní hematologická klinika Lékařské fakulty UK a FN Hradec Králové, přednosta doc. MUDr. Pavel Žák, Ph. D.
Published in the journal: Vnitř Lék 2012; 58(12): 915-921
Category: Original Contributions

Summary

Introduction:
The aim of this study was to assess treatment efficiency, overall survival (OS) and identify risk factors with the influence on patients prognosis in patients with primary central nervous system lymphomas (PCNSL) who were treated with intensive chemotherapy based on high-dose methotrexate and cytosin-arabinoside followed by whole-brain radiotherapy (MPV regimen).

Patients and methods:
From January 1998 to February 2011, 39 patients with PCNSL were diagnosed on our department. The median from the first clinical symptomatology to histological diagnosis was 4 weeks (range, 2–19). Thirty-seven patients were treated with MPV regimen.

Results:
The therapeutic response was evaluated in 35 patients (2 patients died early during treatment). The overall response/complete remission rate was 63/60%. At the time of analysis (november 2011), the median of follow-up was 16,5 months; 31 patients died (the most often causes of death were poor treatment effect and treatment complications). The 2-year OS was 30% and median PFS and OS were 9 and 12 months. Patients with WHO performance status 0–1 and those with normal serum lactate dehydrogenase serum had significantly longer OS (p = 0.0495 and p = 0.0232).

Conclusion:
The treatment results of our patients appear to be inferior than data from literature. The reason is probably high occurrence of negative prognostic factors. Early diagnosis and intensive treatment are crucial for improvement of prognosis.

Keywords:
primary central nervous system lymphoma – chemotherapy – radiotherapy – methotrexate – risk factors – overall survival

Zdroje

1. Singh AD, Lewis H, Schachat AP. Primary lymphoma of the central nervous system. Ophthalmol Clin North Am 2005; 18: 199–207.

2. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006; 24: 1281–1288.

3. Fitzsimmons A, Upchurch K, Batchelor. T Clinical features and diagnosis of primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005; 19: 689–703.

4. Commins DL. Pathology of primary central nervous system lymphoma. Neurosurg Focus 2006; 21: E2.

5. Ferreri AJ, Reni M. Primary central nervous system lymphoma. Crit Rev Oncol Hematol 2007; 63: 257–268.

6. Kluin PM, Ko YH, Kovrigina AM et al. World Health Organisation Classification of Tumors of Haematopoietic and Lymphoid Tissue. Lyon: Agency for Research on Cancer 2008.

7. Almhanna K, Wongchaowart N, Sweetenham J. Intracerebral Hodgkin‘s lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and literature review. Cancer Invest 2009; 27: 215–220.

8. Ferreri AJ, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21: 266–272.

9. Shah GD, DeAngelis LM. Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005; 19: 611–627.

10. Ferreri AJ, Reni M. Prognostic factors in primary central nervous system lymphomas. Hematol Oncol Clin North Am 2005; 19: 629–649.

11. Belada D, Trněný M, Campr V et al. Diagnostické a léčebné postupy u nemocných s maligními lymfomy. Hradec Králové: HK CREDIT, 2009: 72–73.

12. Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009; 8: 581–592.

13. DeAngelis LM, Iwamoto FM. An update on therapy of primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2006: 311–316.

14. Shah GD, Yahalom J, Correa DD et al. Combined immunochemotherapy with reduced whole--brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25: 4730–4735.

15. Belada D, Trněný M. Diagnostické a léčebné postupy u nemocných s maligními lymfomy IV. Hradec Králové: HK CREDIT, 2011: s. 72–73.

16. Belada D, Trněný M. Diagnostické a léčebné postupy u nemocných s maligními lymfomy II. Praha 2007: 76.

17. Abrey LE, Batchelor TT, Ferreri AJ et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034–5043.

18. Hrudková M, Belada D, Smolej L, Žák P, Malý J. Primární lymfomy centrálního nervového systému. Vnitř Lék 2010; 56: 795–800.